




































Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer 
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We conducted imputation to the 1000 Genomes Project of four genome-wide association 
studies of lung cancer in populations of European ancestry (11,348 cases and 15,861 
controls) and genotyped an additional 10,246 cases and 38,295 controls for follow-up. 
We identified large-effect genome-wide associations for squamous lung cancer with the 
rare variants BRCA2 p.Lys3326X (rs11571833, odds ratio (OR) = 2.47, P = 4.74 × 
10−20) and CHEK2 p.Ile157Thr (rs17879961, OR = 0.38, P = 1.27 × 10−13). We also 
showed an association between common variation at 3q28 (TP63, rs13314271, OR = 
1.13, P = 7.22 × 10−10) and lung adenocarcinoma that had been previously reported only 
in Asians. These findings provide further evidence for inherited genetic susceptibility to 
lung cancer and its biological basis. Additionally, our analysis demonstrates that 
imputation can identify rare disease-causing variants with substantive effects on cancer 





Lung cancer causes over 1 million deaths each year worldwide1. Although primarily 
caused by tobacco smoking, studies have also implicated inherited genetic factors in the 
etiology of lung cancer; notably, genome-wide association studies (GWAS) in Europeans 
have consistently identified polymorphic variation at 15q25.1 (CHRNA5-CHRNA3-
CHRNB4), 5p15.33 (TERT-CLPTM1) and 6p21.33 (BAG6 (also called BAT3)-MSH5) as 
determinants of lung cancer risk2–6. Additionally, susceptibility loci for lung cancer at 
3q28, 6q22.2, 13q12.12, 10q25.2 and 22q12.2 in Asians have been identified through 
GWAS7–9. 
 
Non–small cell lung cancer (NSCLC) is the most common lung cancer histology, 
comprised primarily of adenocarcinoma (AD) and squamous cell carcinoma (SQ). These 
lung cancer histologies have different molecular characteristics that reflect differences in 
etiology and carcinogenesis10. Perhaps not surprisingly, there is variability in the genetic 
effects on lung cancer risk by histology, with subtype-specific associations at 5p15.33 
(TERT-CLPTM1) for AD11,12 and at 9p21 (CDKN2A/CDKN2B)13 and 12q13.33 
(RAD52)14 for SQ. In addition, the 6p21.33 associations are stronger for SQ than for 
AD13. 
 
To identify additional lung cancer susceptibility loci, we conducted a meta-analysis of 
four lung cancer GWAS in populations of European ancestry: the MD Anderson Cancer 
Center (MDACC) GWAS, the Institute of Cancer Research (ICR) GWAS, the National 
Cancer Institute (NCI) GWAS and the International Agency for Research on Cancer 
(IARC) GWAS (Online Methods), which were genotyped using Illumina HumanHap 
317, 317+240S, 370Duo, 550, 610 or 1M arrays (Supplementary Table 1). After 
filtering, the studies provided genotypes on 11,348 cases and 15,861 controls 
(Supplementary Table 1). Before undertaking meta-analysis of the GWAS data, we 
searched for potential errors and biases in the data sets. Quantile-quantile (Q-Q) plots of 
genome-wide association test statistics showed minimal inflation, rendering substantial 
cryptic population substructure or differential genotype calling between cases and 
controls unlikely (λ = 1.01–1.05; Supplementary Fig. 1). To bring genotype data 
obtained from different arrays into a common platform and recover untyped genotypes, 
we imputed >10 million SNPs using 1000 Genomes Project data as the reference. Q-Q 
plots for all SNPs and those restricted to rare SNPs (minor allele frequency (MAF) <1%) 
after imputation did not show evidence of substantive overdispersion introduced by 
imputation (λ = 0.99–1.06 and λ = 0.82–1.05, respectively; Supplementary Fig. 1). 
Pooling data from each GWAS, we derived joint ORs and 95% confidence intervals 
(CIs) under a fixed-effects model for each SNP and the associated per-allele P values. To 
explore variability in associations according to tumor histology, we derived ORs for all 
lung cancer, AD and SQ. 
 
Our meta-analysis identified 50 SNPs that showed evidence of association with lung 
cancer, AD or SQ (P < 5.0 × 10−6; Fig. 1) at loci not reported previously in Europeans 
(Fig. 1). We evaluated 1-Mb regions encompassing these 50 SNPs for association through 
in silico replication in the Harvard15 and deCODE16 series. Nine of the SNPs within 
these 50 regions showed support for an association (combined P < 5.0 × 10−7). We 
attempted genotyping of these nine SNPs in four additional series: the Heidelberg–
European Prospective Investigation into Cancer and Nutrition (EPIC), ICR, IARC and 
Toronto replications (Supplementary Table 2b and Online Methods). rs185577307 
could not be genotyped because of repetitive sequence. Collectively, genotypes were 
available from 21,594 cases and 54,156 controls, providing 80% power to detect a variant 
with MAF of 0.01 and conferring a relative risk of ≥1.5. In the combined analysis of all 
GWAS plus replication series data, SNPs mapping to 13q13.1 (rs11571833 and 
rs56084662), 22q12.1 (rs17879961) and 3q28 (rs13314271) showed evidence for 
association, which was statistically significant after adjustment for multiple testing (P < 
3.0 × 10−9; Fig. 2 and Supplementary Table 3). We confirmed the high fidelity of 
imputation by genotyping rs11571833, rs17879961 and rs13314271 in subsets of the ICR, 
IARC, NCI and MDACC GWAS (Supplementary Table 2 and Online Methods). The 
NCI GWAS comprised samples from Finland, Italy and the United States. The IARC 
GWAS comprised samples from ten series from western and eastern Europe and the 
United States. Although adjustment of test statistics for principal components generated 
on common SNPs had been applied to these GWAS, confounding of rare variants in 
spatially structured populations is not necessarily corrected by such methods17. We 
therefore investigated whether country of origin had an impact on the associations at 
13q13.1 and 22q12.1; the associations remained statistically highly significant (P < 5.0 × 
10−8; Supplementary Table 4). 
 
rs11571833 and rs56084662, localizing to 13q13.1 near or within BRCA2, are rare 
(MAF < 0.01), map 103 kb apart (32,972,376 bp and 32,869,614 bp, respectively) and 
are moderately correlated (r2 = 0.45 and D′ = 0.82 based on genotypes from the 
Heidelberg-EPIC, IARC, ICR and Toronto replication series; Fig. 3). rs11571833 
(c.9976A>T) is responsible for BRCA2 p.Lys3326X, whereas rs56084662 is located in 
the 3′ UTR of FRY. Although the association provided by rs11571833 was substantially 
stronger than that provided by rs56084662 in the combined analysis (OR = 1.83, P = 2.11 
× 10−19 and P = 1.88 × 10−15, respectively), a conditional analysis based on directly 
genotyped samples in the replication series was consistent with the two SNPs tagging the 
same haplotype. The association at rs11571833 is driven primarily by a relationship with 
SQ histology rather than AD histology (OR = 2.47, P = 4.74 × 10−20 and OR = 1.47, P 
= 4.66 × 10−4, respectively; Fig. 2 and Supplementary Table 3). A stronger role for 
BRCA2 in SQ etiology than in AD etiology is reflected in the higher observed mutational 
frequency in the respective lung cancers (~6% and 1% (refs. 18,19)). Thr9976 was 
recently shown to confer a 1.26-fold increased breast cancer risk20 and has been 
suggested previously as a risk factor for esophageal and pancreatic cancers21,22. We 
found no evidence for an association between Thr9976 and lung cancer risk in 
nonsmokers using directly genotyped samples (Supplementary Table 2); however, these 
cases comprised <10% of each cohort, and therefore our power to demonstrate a 
relationship was limited. Previous analyses of families carrying highly penetrant BRCA2 
mutations have found either no evidence for any excess risk or a reduced risk of lung 
cancer in carriers23,24. A possible explanation for these observations is that members of 
the families studied tended to smoke less than the general population24. 
 
The RAD51-BRCA2 interaction is pivotal for BRCA2-mediated double strand–break 
repair, and exon 27 of BRCA2 encodes one of the highly conserved RAD51 binding 
domains: homozygous deletion of exon 27 in mice confers susceptibility to tumors, 
including lung cancer25. Thr9976 leads to the loss of the C-terminal domain of BRCA2, 
inviting speculation that the SNP is functional. Although the deleted region is distal to 
the RAD51 binding domain and an impact on nuclear localization is unknown26,27, the 
nearby BRCA2 p.Thr3387Ala alteration interrupts CHK2 phosphorylation and abrogates 
BRCA2-CHK2-RAD51–mediated recombination repair28. Alternatively, the association 
might be a consequence of linkage disequilibrium (LD) with another BRCA2 mutation. 
Studies of families with breast cancer of northern European ancestry show that the BRCA2 
c.6275delTT and c.4889C>G mutations, which are highly penetrant for breast and ovarian 
cancer, originated on a p.Lys3326X haplotype29. To gain further insight into a probable 
genetic basis of the 13q13.1 lung cancer association, we sequenced germline DNA from 
70 individuals with lung cancer who carried c.9976A>T from the UK Genetic Lung 
Cancer Predisposition Study for the c.6275delTT and c.4889C>G mutations; we did not 
find c.6275delTT or c.4889C>G in any of these individuals. Similarly, sequencing the 
coding region of BRCA2 identified no clearly pathogenic mutations among 13 individuals 
from the 1958 British Birth Cohort (58BC), 11 individuals with lung cancer from IARC 
or 24 individuals with lung cancer carrying Thr9976 from TCGA. In Iceland, Thr9976 is 
not correlated with the founder BRCA2 mutation resulting in p.256_257del (c.999del5), 
which greatly increases the risk of breast and ovarian cancer. Paradoxically, whereas 
Thr9976 is a risk factor for lung cancer, in this population this SNP is not associated with 
risk of breast or ovarian cancer (Supplementary Table 5). Although in vitro studies have 
failed to demonstrate that p.Lys3326X affects DNA repair30, our findings raise the 
possibility that p.Lys3326X may have a direct effect on lung cancer risk. The fact that 
somatic mutation of BRCA2 is not associated with p.Lys3326X carrier status19 
(Supplementary Table 6a) suggests that any impact the SNP has on lung cancer risk is 
mediated through alternative mechanisms. 
The relationship at 22q12.1 between the rs17879961 (c.470T>C) and SQ in the 
combined series (OR = 0.38, P = 1.27 × 10−13) validates an association that has been 
reported previously31,32 (Fig. 2 and Supplementary Tables 3 and 4). The frequency of 
rs17879961 varies markedly between populations: it has a MAF of ~5% in eastern 
Europeans (for example, individuals in the IARC series) but is almost monomorphic in 
most northern Europeans. This likely accounts for the failure to demonstrate a significant 
relationship in the ICR, MDACC, Toronto and deCODE series, which comprise largely 
western European populations (Fig. 2 and Supplementary Table 3). rs17879961 is 
responsible for the missense mutation in CHEK2 resulting in p.Ile157Thr; CHEK2 is a 
cell cycle–control gene encoding a pluripotent kinase that can cause arrest or apoptosis in 
response to DNA damage. Acquired mutation of CHEK2 is rarely seen in lung cancer, 
and the CHEK2 p.Ile157Thr alteration does not appear to correlate with mutation 
(Supplementary Table 6a), raising the possibility that carrier status per se influences 
cancer risk. The p.Ile157Thr substitution lies in a functionally important domain of 
CHEK2 and causes reduced or abolished binding of principal substrates. Although 
Cys470 increases breast cancer risk33, here Cys470 was associated with reduced lung 
cancer risk. A mechanism for the paradoxical associations is not immediately apparent. 
However, CHEK2 can have opposite effects on damaged stem cells, retarding stem cell 
division until DNA damage is repaired or activating apoptosis if damage cannot be 
repaired. Although speculative, in the presence of continued DNA damage to squamous 
epithelia by tobacco smoke, the normal stem cell defenses involving CHEK2 might be 
attenuated by a reduction in CHEK2 activity as a result of p.Ile151Thr31. Concordant 
with such a model is our observation of a paradoxically increased lung cancer risk in 
nonsmokers (P = 0.05) and in correlated subgroups of AD and women, although this 
increase was based on small numbers (Supplementary Table 2). 
 
The association between variation at 3q28 marked by rs13314271 and lung cancer risk 
was restricted to AD (OR = 1.13, P = 7.22 × 10−10; Fig. 2 and Supplementary Table 
3). rs13314271 maps within intron 1 of TP63 (Fig. 3). Variation at TP63 defined by the 
intron 1 SNP rs4488809, which is in complete LD with rs13314271 (r2 = 1.00, D′ = 1.00), 
is associated with AD in Asians8. Our findings provide robust evidence for the 
generalizability of a relationship between 3q28 variation and AD. We found a weak 
association between rs13314271 and lung cancer risk in nonsmokers (P = 0.03; 
Supplementary Table 2b). TP63 is a member of the tumor suppressor TP53 gene family, 
which is pivotal in cellular differentiation and responsiveness to cellular stress34,35. 
Exposure of cells to DNA damage leads to induction of TP63, and both isoforms have the 
ability to transactivate TP53 target genes, thereby affecting cellular responsiveness to 
DNA damage36. Although rs13314271 does not map to an evolutionary conserved 
region, rs7636839, which is correlated with rs13314271 and rs4488809 (r2 = 1.0), does 
map to an evolutionarily conserved region and has predicted enhancer activity 
(Supplementary Table 6b). Moreover, rs4488809 has been shown to be an expression 
quantitative trait locus for TP63 in lung tissue37. Although the mechanism by which 3q28 
variation affects AD development is unknown, accumulation of DNA damage and a lack 
of response to genotoxic stress are recognized to contribute to lung carcinogenesis; hence, 
loss of repair fidelity as a consequence of differential TP63 expression is likely 
deleterious. 
 
There was no association between rs11571833, rs17879961 and rs13314271 genotypes 
and cigarette consumption on the basis of smoking information on 43,693 Icelandic 
subjects (Supplementary Table 7), which is in contrast to the association of 15q25 and 
risk of lung cancer. 
 
Although there is some overlap, distinct DNA lesions are ostensibly repaired by different 
DNA repair pathways. Histology-specific relationships seen implicate the BRCA2-
CHEK2-RAD52 double strand–break repair and homologous recombination pathways as 
a determinant of SQ and defective TP53 and TERT apoptosis-telomerase regulation as a 
basis of AD risk. In conclusion, our findings provide further evidence for inherited genetic 
susceptibility to lung cancer and underscore the importance of searching for histology-
specific risk variants. Our data also provide an important proof of principle that 1000 
Genomes imputation can be used to detect new, low-frequency, large-effect associations, 
thereby extending the utility of preexisting GWAS data. Notably, this study facilitated 
the identification of BRCA2 Thr9976, which is the strongest genetic association in lung 
cancer reported so far. For a smoker carrying this variant (2% of the population), the risk 
of developing lung cancer is approximately doubled, which may have implications for 
identifying high-risk ever-smoking subjects for lung cancer screening. Additionally, 
future study of the effects of PARP inhibition in smokers with lung cancer carrying 
BRCA2 Thr9976 may be warranted. 
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Figures 
Figure 1 Genome-wide P values plotted against their respective chromosomal positions. 
(a–c) All lung cancer (a), AD (b) and SQ (c). Shown are the genome-wide P values (two 
sided) obtained using the Cochran-Armitage trend test from analysis of 8.9 million 
successfully imputed autosomal SNPs in 11,348 cases and 15,861 controls from the 
discovery phase. The red and blue horizontal lines represent the significance thresholds 
of P = 5.0 × 10−8 and P = 5.0 × 10−6, respectively. Any region that contained at least one 
association signal better than P = 5.0 × 10−6 was selected for the in silico replication. 
 
  
Figure 2 Plots of the ORs of lung cancer associated with 13q13.1 (rs11571833 and 
rs56084662), 22q12.1 (rs17879961) and 3q28 (rs13314271) risk loci. (a–l) All lung 
cancer based on 21,594 lung cancer cases and 54,156 controls (a–d), SQ based on 6,477 
SQ cases and 53,333 controls (e–h) and AD based on 7,031 AD cases and 53,189 controls 
(i–l). The studies are weighted according to the inverse of the variance of the log of the 
OR calculated by unconditional logistic regression. Horizontal lines indicate the 95% CIs. 
Boxes are the OR point estimates, and the area of the box is proportional to the weight of 
the study. Diamonds and broken lines indicate the overall summary estimate derived 
under a fixed-effects (FE) model, with the CI given by the width. Unbroken vertical lines 
show the null value (OR = 1.0). 
 
  
Figure 3 Regional plots of associations at susceptibility loci for SQ and AD. (a–c) 
Association results and recombination rates for the 13q13.1 in SQ (a), 22q12.1 in SQ (b) 
and 3q28 in AD (c). The SQ-related plots (a,b) were based on 3,275 SQ cases and 15,038 
controls from the discovery phase; the AD-related plot (c) was based on 3,442 AD cases 
and 14,894 controls from the discovery phase. Association results of both genotyped 
(circles) and imputed (diamonds) SNPs in the GWAS samples and recombination rates 
for each locus are shown. For each plot, −log10 P values (y axes) of the SNPs are shown 
according to their chromosomal positions (x axes). The top genotyped SNP in each 
combined analysis is indicated by a large diamond and is labeled by its rsID. The color 
intensity of each symbol reflects the extent of LD with the top genotyped SNP: white (r2 
= 0) through to dark red (r2 = 1.0). Genetic recombination rates (cM/Mb), estimated using 
HapMap CEU samples, are shown with a light blue line. Physical positions are based on 
NCBI build 37 of the human genome. Also shown are the relative positions of genes and 
transcripts mapping to each region of association. Genes have been redrawn to show the 
relative positions; therefore, maps are not to physical scale. 
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Online Materials & Methods 
Studies. 
The study was conducted under the auspices of the Transdisciplinary Research In Cancer 
of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and 
MEchanisms in ONcology (GAME-ON) consortium and is associated with the 
International Lung Cancer Consortium (ILCCO). Tumors from patients were classified 
as AD, SQ, large-cell carcinoma (LCC), mixed adenosquamous carcinoma (MADSQ) 
and other NSCLC histologies following either the International Classification of Diseases 
for Oncology (ICD-O) or WHO coding. Tumors with overlapping histologies were 
classified as mixed. 
Ethics. 
All participants provided informed written consent. All studies were reviewed and 
approved by institutional ethics review committees at the involved institutions. 
GWAS. 
The meta-analysis was based on data from four previously reported lung cancer GWAS 
of European populations: the MDACC GWAS3, the ICR GWAS6, the NCI GWAS13 
and the IARC GWAS2. In each of the studies, SNP genotyping had been performed using 
Illumina HumanHap 317, 317+240S, 370, 550, 610 or 1M arrays (Supplementary Table 
1). 
IARC GWAS. The IARC GWAS2 comprised 3,062 lung cancer cases and 4,455 controls 
derived from five case-control studies: (i) the Carotene and Retinol Efficacy Trial 
(CARET) cohort38; (ii) the Central Europe multicenter hospital-based case-control 
study39,40; (iii) the hospital-based case-control study from France40; (iv) the hospital-
based case-control lung cancer study from Estonia41,42; and (v) the population-based 
HUNT2/Tromsø IV lung cancer studies43. Patient and control DNAs were derived from 
EDTA–venous blood samples. The patients with lung cancer were classified according to 
ICD-O-3: SQ: 8070/3, 8071/3, 8072/3, 8074/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 
8480/3, 8560/3, 8251/3, 8490/3, 8570/3, 8574/3; with tumors with overlapping 
histologies being classified as mixed. After applying standardized quality-control 
procedures, 2,533 cases and 3,791 controls were included in the current analysis 
(Supplementary Table 1). 
NCI GWAS. Details of the NCI GWAS have been reported previously. Briefly, the study 
comprised samples from four series: (i) the Environment and Genetics in Lung cancer 
Etiology (EAGLE) study, a population-based case-control study of 2,100 lung cancer 
cases and 2,120 healthy controls enrolled in Italy between 2002 and 2005 (ref. 44), in 
which cancers were classified according to the ICD-O coding for histology and grading 
and histology of ~10% of tumors was confirmed by an independent pathologist from the 
NCI; (ii) the α-Tocopherol, β-Carotene Cancer Prevention Study (ATBC), a randomized 
primary prevention trial of 29,133 male smokers enrolled in Finland between 1985 and 
1993 (ref. 45), in which ICD-O-2 and ICD-O-3 were used to classify tumors and cases 
diagnosed between 1985 and 1999 had histology reviewed by at least one pathologist 
(after 1999, histological coding (ICD-O-2 and ICD-O-3) was derived from the Finnish 
Cancer Registry); (iii) the Prostate, Lung, Colon, Ovary Screening Trial (PLCO), a 
randomized trial of 150,000 individuals enrolled in 10 US study centers between 1992 
and 2001 (ref. 46), in which ICD-O-2 was used to classify tumors and quality assurance 
measures included reabstraction of 50 lung cancer diagnoses per year; and (iv) the Cancer 
Prevention Study II Nutrition Cohort (CPS-II), a cohort study of approximately 184,000 
individuals enrolled by the American Cancer Society between 1992 and 1993 in 21 US 
states, of which 109,379 provided a blood (36%) or buccal (64%) sample between 1998 
and 2003 (refs. 12,47) and tumor histology was abstracted from Certified Tumor 
Registrars and coded using WHO ICD-O-2 and ICD-O-3. In this study, quality assurance 
was done by reabstracting 10% of all cancer diagnoses per year. After initial data quality 
control, the NCI GWAS included 5,739 cases and 5,848 controls; however, an additional 
26 cases and 112 controls were excluded because of changes in case status and further 
quality-control filtering. The current meta-analysis included 5,713 lung cancer cases and 
5,736 controls from the NCI GWAS (Supplementary Table 1). 
ICR GWAS. The ICR GWAS comprised 1,952 cases (1,166 male; mean age at diagnosis 
57 years, s.d. 6 years) with pathologically confirmed lung cancer ascertained through the 
Genetic Lung Cancer Predisposition Study (GELCAPS) conducted between March 1999 
and July 2004 (ref. 48). All cases were British residents and were self-reported to be of 
European ancestry. To ensure that data and samples were collected from bona fide lung 
cancer cases and avoid issues of bias from survivorship, only incident cases with 
histologically or cytologically (if not AD) confirmed primary disease were ascertained. 
Tumors from patients were classified according to ICD-O3: specifically, SQ: 8070/3, 
8071/3, 8072/3, 8074/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3, 8560/3, 8251/3, 
8490/3, 8570/3, 8574/3; with tumors with overlapping histologies being classified as 
mixed. Patient DNA was derived from EDTA–venous blood samples using conventional 
methodologies. Genotype frequencies were compared with publicly accessible data 
generated by the UK Wellcome Trust Case-Control Consortium 2 (WTCCC2) study49 of 
individuals from the 1958 British Birth Cohort (58BC), and blood service was typed using 
Illumina Human1.2M-Duo Custom_v1 Array BeadChips. 
MDACC GWAS. Cases and controls were ascertained from a case-control study at the 
University of Texas MD Anderson Cancer Center conducted between 1997 and 2007 (ref. 
3). Cases were newly diagnosed patients with histologically confirmed lung cancer 
presenting at MD Anderson Cancer who had not previously received treatment other than 
surgery. Clinical and pathological data were abstracted from patient medical records, and 
lung cancer histology was coded according to the major histological groups. Specifically, 
as per ICD-O-2, these groups were SQ: 8070/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 
8480/3, 8251/3, 8490/3. Only patients with predominantly or wholly AD or SQ cancers 
were included; those with mixed histology or unspecified lung cancers were excluded 
from the study. Controls were healthy individuals seen for routine care at Kelsey-Seybold 
clinics in the Houston metropolitan area. Controls were frequency matched to cases 
according to smoking behavior, age in 5-year categories, ethnicity and sex. Former 
smoking controls were further frequency matched to former smoking cases according to 
the number of years since smoking cessation (in 5-year categories). After applying quality 
controls, data were available on 1,150 cases and 1,134 controls. 
Quality control of GWAS data sets. 
Standard quality control was performed on all scans, excluding individuals with low call 
rate (<90%) and extremely high or low heterozygosity (P < 1.0 × 10−4), as well as all 
individuals evaluated to be of non-European ancestry (using the HapMap version 2 CEU, 
JPT/CHB and YRI populations as a reference; Supplementary Table 1). For apparent 
first-degree relative pairs, we removed the control from a case-control pair; otherwise, we 
excluded the individual with the lower call rate. 
Replication series. 
To validate promising associations from the meta-analysis, we made use of in silico data 
and imputed genotypes from Harvard and deCODE GWAS data sets together with data 
from the direct-genotyping Heidelberg-EPIC, ICR, IARC and Toronto replication series. 
Harvard. For the Harvard Lung Cancer Susceptibility Study, details of participant 
recruitment have been described previously50. Replication was based on data derived 
from 1,000 cases and 1,000 controls genotyped using Illumina HumanHap610-Quad 
arrays. Cases were patients aged >18 years with newly diagnosed, histologically 
confirmed primary NSCLC. Controls were healthy non–blood related family members 
and friends of patients with cancer or with cardiothoracic conditions undergoing surgery. 
The histological classification of lung tumors was performed by two staff pulmonary 
pathologists at Massachusetts General Hospital according to ICD-O-3: specifically, AD: 
8140/3, 8250/3, 8260/3, 8310/3, 8480/3 8560/3; LCC: 8012/3, 8031/3; SQ: 8070/3, 
8071/3, 8072/3, 8074/3; other NSCLC: 8010/3, 8020/3, 8021/3, 8032/3, 8230/3. 
Unqualified samples were excluded if they fit the following quality-control criteria: (i) 
overall genotype completion rates <95%; (ii) gender discrepancies; (iii) unexpected 
duplicates or probable relatives (based on a pairwise identity-by-state value of PI_HAT 
in PLINK >0.185); (iv) heterozygosity rates >6 times the s.d. from the mean; or (v) 
individuals evaluated to be of non-European ancestry (using HapMap release 23 
including the JPT, CEPH, CEU and YRI populations as a reference). Unqualified SNPs 
were excluded when they fit the following quality-control criteria: (i) SNPs were not 
mapped on autosomes; (ii) SNPs had a call rate <95% in all GWAS samples; (iii) SNPs 
had MAF <0.01; or (iv) the genotype distributions of SNPs deviated from those expected 
by Hardy-Weinberg equilibrium (P < 1.0 × 10−6). After applying these prespecified 
quality controls, genotype data were available for 984 cases and 970 controls. 
deCODE. The Icelandic lung cancer study has been described previously4. The primary 
source of information on the Icelandic lung cancer cases is the Icelandic Cancer Registry 
(ICaR), which covers the entire population of Iceland 
(http://www.cancerregistry.is/krabbameinsskra/indexen.jsp?id=summary). The sources 
of data in the ICaR are all pathology and hematology laboratories and all hospital 
departments and health care facilities in the country. ICaR registration is based on the 
ICD system and includes information on histology (systemized nomenclature of 
medicine, SNOMED). ICaR registration also uses the ICD-O system, which takes 
histology diagnosis into account. Over 94% of diagnoses in the ICaR have histological 
confirmation. Briefly, according to the ICaR, a total of 4,252 patients were diagnosed 
with lung cancer from January 1, 1955 to December 31, 2010. Recruitment of both 
prevalent and incident cases was initiated in 1998, the recruitment is ongoing and DNA 
samples from lung cancer cases are subjected to whole-genome genotyping as they are 
collected. The controls used in this study consisted of individuals from other GWAS that 
were age and sex matched to cases, with no individual disease group accounting for >10% 
of all controls. Samples were assayed with the Illumina HumanHap300, HumanCNV370, 
HumanHap610, HumanHap1M, HumanHap660, Omni-1, Omni 2.5 or Omni Express 
bead chips at deCODE genetics. SNPs were excluded if they had (i) a yield <95%, (ii) 
MAF < 1% in the population, (iii) deviation from Hardy-Weinberg equilibrium (HWE; P 
< 10−6), (iv) inheritance error rate (>0.001) or (v) if there was a substantial difference in 
allele frequency between chip types (in which case the SNP was removed from a single 
chip type if that resolved the difference, but if it did not then the SNP was removed from 
all chip types). All samples with a call rate of <97% were removed from the analysis. The 
Icelandic sample set is drawn from the Icelandic population, which is a small 
homogeneous founder population with almost no detectable population substructure. 
Thus, there was no need to adjust for such substructure in the association analysis. In 
addition, the comprehensive Icelandic genealogy database allowed us to exclude 
individuals not of Icelandic origin from the analysis. SNP genotypes were phased using 
the method of long-range phasing51; for the HumanHap series of chips, 304,937 SNPs 
were used for long-range phasing, whereas for the Omni series of chips, 564,196 SNPs 
were used. An initial imputation step was carried out on each chip series separately to 
create a single harmonized, long-range phased genotype data set consisting of 707,525 
SNPs for 95,085 Icelandic individuals. Two sets of genotypes were imputed into this data 
set with methods previously described52: (i) genotypes for about 38 million variants 
using the 1000 Genomes phase I integrated variant set (v3) as training set and (ii) 
genotypes for about 34 million variants identified in 2,230 whole genome–sequenced 
Icelanders. The first set of imputed genotypes was used for replicating the association 
with variants in the 5p15.33, 9p21 and 12q13.33 regions using IMPUTE (v2.1.1)53 to 
perform the case-control analysis. The second set was used when testing the relationship 
between the p.Lys3326X and c.999del5 genotypes and risk of different cancer types in 
the Icelandic population using a method that allowed including individuals that had not 
been chip typed but for whom genotype probabilities were imputed using methods of 
familial imputation51. 
Heidelberg-EPIC. This study comprised 1,253 Heidelberg-EPIC controls and 1,362 lung 
cancer cases from the Heidelberg lung cancer study recruited between 1994 and 1998 and 
between 1996 and 2007, respectively. Details of the Heidelberg-EPIC controls and the 
Heidelberg lung cancer study have been described previously54,55. All subjects were 
aged 18 years or older, and information on lifestyle risk factors and medical and family 
history was collected through interviews based on standardized questionnaires. The EPIC 
Lung and the Heidelberg-EPIC studies were performed independently with no sample 
overlap with those analyzed as part of the IARC replication series. Histological 
classification of tumors was obtained from pathology reports, where it was recorded by a 
staff pulmonary pathologist according to WHO guidelines. Blood samples from patients 
with malignant lung disease categorized as follows were included: AD, SCLC, NSCLC, 
LCC, carcinoid, mixed lung tumors or mixed without SCLC. The above-described EPIC 
Lung and Heidelberg-EPIC studies were performed independently with no sample 
overlap. Genotypes for SNPs showed no significant departure from HWE, with the 
exception of rs13314271 in cases. 
ICR replication. This study comprised 2,448 cases (1,664 male; mean age at diagnosis 
71.8 years, s.d. 6.7 years) with pathologically confirmed lung cancer ascertained through 
GELCAPS48 and 2,989 controls (1,469 male; mean age at sampling 60.6 years, s.d. 12.0 
years) collected through the National Study of Colorectal Cancer Genetics56 with no 
personal history of malignancy. Cases were subclassified into histological subtypes based 
on ICD coding as described above (in the section detailing the ICR GWAS). Both cases 
and controls were British residents and had self-reported European ancestry. The 
genotype distributions of genotypes for each of the SNPs typed in replication showed no 
significant departure from HWE. 
IARC replication. This analysis comprised three studies: (i) EPIC Lung2,57, a nested 
case-control study performed within the EPIC (European Prospective Investigation into 
Cancer and Nutrition) prospective cohort totaling 1,119 lung cancer cases and 2,546 
controls (matched one or two to cases for age, sex, center and time of recruitment) 
selected from 8 of the 10 countries participating in EPIC (Sweden, Netherlands, UK, 
France, Germany, Spain, Italy and Norway); (ii) the Szczecin case-control study32, a 
consecutive series of 849 incident lung cancer cases ascertained from the outpatient 
oncology clinic in the regional hospital of Szczecin between 2004 and 2007 (the 1,072 
controls were individuals without diagnosed cancer or family history of cancer matched 
to cases by sex, age and region recruited by general medical practitioners); and (iii) 
Moscow L2, 1,081 newly diagnosed lung cancer cases and 2,119 controls recruited from 
three hospitals within the Moscow area of Russia between 2007 and 2011. Information 
on lifestyle risk factors and medical and family history was collected from subjects by 
interview using a standard questionnaire. Cases were subclassified into histological 
subtypes based on ICD-O3 coding as described above (in the section detailing the IARC 
GWAS). The distributions of genotypes for each of the SNPs typed in replication showed 
no departure from HWE in each country or study series. 
Toronto. This study was conducted in the greater Toronto area from 2008 to 2013. Lung 
cancer cases were recruited at the hospitals in the network of the University of Toronto. 
Controls were selected randomly from individuals registered in the family medicine 
clinics databases and were frequency matched with cases on age and sex. All subjects 
were interviewed, and information on lifestyle risk factors, occupational history and 
medical and family history was collected using a standard questionnaire. Tumors were 
centrally reviewed by the reference pathologist (a member of the International 
Association for the Study of Lung Cancer (IASLC) committee) and a second pathologist 
in the University Health Network. If the reviews conflicted, a consensus was arrived at 
after discussion. Coding of histology was based on 2001 WHO/IASLC. After applying 
standardized quality control procedures and restricting the data to participants with self-
reported European ancestry, data and samples were available on 1,084 cases and 966 
controls. The genotype distributions of genotypes for each of the SNPs typed in 
replication showed no significant departure from HWE. 
Replication genotyping. 
Genotyping of rs1519542, rs13314271, rs55731496, rs149423192, rs4592420, 
rs11571833, rs56084662 and rs17879961 was performed using competitive allele-
specific PCR KASPar chemistry (LGC, Hertfordshire, UK; UK replication series), 
Sequenom (Sequenom, Inc., San Diego, US; Toronto replication and Heidelberg-EPIC 
replication (rs1519542, rs55731496, rs149423192, rs4592420, rs11571833, rs56084662 
and rs17879961)) or TaqMan (Carlsbad, CA; IARC replication series and Heidelberg-
EPIC replication (rs13314271)). All primers, probes and conditions used are available on 
request. Call rates for SNP genotypes were >95% in each of the replication series. 
To ensure the quality of genotyping in all assays, at least two negative controls and 1–
10% duplicates (showing a concordance of >99%) were genotyped at each center. To 
exclude technical artifacts in genotyping, at the ICR and IARC we performed cross-
platform validation of 96 samples and sequenced a set of 96 randomly selected samples 
from each case and control series to confirm genotyping accuracy. Assays were found to 
be performing robustly; concordance was >99%. 
Statistical and bioinformatic analyses. Data were imputed for all scans for over 10 million 
SNPs using data from the 1000 Genomes Project (phase 1 integrated release 3, March 
2012) as reference using IMPUTE2 v2.1.1 (ref. 53), MaCH58 v1.0 or minimac (version 
2012.10.3)59 software (Supplementary Table 1). Genotypes were aligned to the positive 
strand in both imputation and genotyping. Imputation was conducted separately for each 
scan in which each GWAS data set was pruned to a common set of SNPs between cases 
and controls before imputation. As previously described, we set thresholds for imputation 
quality to retain both potential common and rare variants for validation13,60. 
Specifically, poorly imputed SNPs defined by an RSQR < 0.30 with MaCH or an 
information measure Is < 0.40 with IMPUTE2 were excluded from the analyses. Tests of 
association between imputed SNPs and lung cancer were performed under a probabilistic 
dosage model in SNPTEST v2.5 (ref. 61), ProbABEL62, MaCH2dat v.124 (ref. 58) or 
the glm function in R. Principle components generated using common SNPs were 
included in the analysis to limit the effects of cryptic population stratification that might 
cause inflation of test statistics. The association between each SNP and lung cancer risk 
was assessed by Cochran-Armitage trend test. The adequacy of the case-control matching 
and possibility of differential genotyping of cases and controls were formally evaluated 
using Q-Q plots of test statistics. Meta-analysis was undertaken using inverse-variance 
approaches. The inflation factor λ was based on the 90% least-significant directly typed 
SNPs63. ORs and associated 95% CIs were calculated by unconditional logistic 
regression using R (v2.6), Stata v.10 (State College, Texas, US) and PLINK64 (v1.06) 
software. Cochran’s Q statistic to test for heterogeneity and the I2 statistic to quantify the 
proportion of the total variation due to heterogeneity were calculated65. I2 values ≥75% 
are considered to be characteristic of large heterogeneity65. Additionally, analyses 
stratified by histology, sex, age and smoking status (current, former or never) were 
performed. All statistical tests were two sided. 
The fidelity of imputation as assessed by the concordance between imputed and directly 
genotyped SNPs was examined in a subset of samples from the UK GWAS, MDACC 
GWAS, IARC GWAS and NCI GWAS discovery series (Supplementary Table 2). 
LD metrics were calculated in PLINK using 1000 Genomes data and plotted using 
SNAP66. LD blocks were defined on the basis of HapMap recombination rate (cM/Mb) 
as defined using the Oxford recombination hotspots and on the basis of the distribution 
of CIs defined by Gabriel et al.67. 
Relationship between genotypes and smoking. 
To examine the relationship between rs11571833 (BRCA2 p.Lys3326X), rs17879961 
(CHEK2 p.Ile157Thr) and rs13314271 (TP63) genotype and cigarette consumption 
(cigarettes per day)68, we used data on 43,693 Icelandic subjects (including 34,850 chip-
typed individuals). 
Sequence analysis of BRCA2 in constitutional DNA. 
At the ICR, targeted sequencing for the BRCA2 mutations c.6275delTT and c.4889C>G 
was performed by Sanger implemented on an ABI3700 analyzer (Applied Biosystems; 
primer sequences and conditions are available on request). Mutational analysis of the 
complete coding region of BRCA2 was based on exome sequencing data generated using 
Illumina TruSeq capture technology (Illumina, Inc, San Diego, USA). Analysis of 
Illumina HiSeq2000 (Illumina, Inc, San Diego, USA) sequence data was performed using 
an in-house pipeline based on the GATK tool kit. 
At IARC, Qiagen Generead (SABiosciences/Qiagen Hilde, Germany) was used to 
amplify the coding region of BRCA2 in rs11571833 heterozygotes. 
After library preparation (New England BioLabs, Ipswich, MA, USA), sequencing was 
performed using an IonTorrent PGM desktop sequencer (Life Technologies, Guilford, 
San Francisco, CA). Genotypes were called using Ionsuite software. Sequence changes 
were referenced to the Leiden Open Variation Database (LOVD2) and the BReast CAncer 
IARC database. 
Analysis of TCGA data. 
The exomes of 243 individuals with lung SQ and 338 individuals with lung AD in TCGA 
(Project Number #3230) were analyzed at IARC using an in-house pipeline based on the 
GATK tool set. Variant calls were annotated using ANNOVAR, making use of use the 
National Heart, Lung, and Blood Institute’s Exome Sequencing Project and 1000 
Genomes data. 
Copy number variation. Copy number variation was assessed from Human SNP Array 
6.0 data. We retrieved level 3 TCGA data comprising normalized log2 ratios of the 
fluorescence intensities between the target sample and a reference sample. We included 
only tumor-normal paired data in our analysis. We considered a log2 ratio ≤0.5 as 
reflecting loss and a log2 ratio >0.5 as reflecting gain. Annotation was performed by 
adding the genes contained in each of the remaining segments using EnsEMBL databases. 
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Supplementary Figure 
Supplementary Figure 1 Q-Q plots of Cochran-Armitage trend test statistics for 
association based on 11,348 cases and 15,861 controls from discovery phase GWASs pre-
imputation (a-d); all SNPs post-imputation (e-h) and rare SNPs post-imputation (i-l). 
 
